US Edition
Ozempic and Wegovy Maker Novo Nordisk Sees Shares Tumble on Profit Alert
DENMARK, JUL 28 – Novo Nordisk cut 2025 sales growth forecast to 8-14% due to competition from copycat semaglutide drugs and slower market expansion in the US, impacting earnings guidance.
- Novo Nordisk has indicated that growth in its annual revenue and earnings will decelerate due to heightened market difficulties and the rise of imitation weight-loss medications.
- The warning follows persistent use of compounded semaglutide copies, FDA rules allowing such compounding after shortages, and strong competition from Eli Lilly.
- The company cut its sales growth forecast to 8–14% from 13–21%, expects earnings growth of 10–16%, and named Maziar Mike Doustdar as the new CEO starting August 7.
- Analyst Søren Løntoft Hansen described the significant forecast reduction as indicative of the current difficulties faced in the US market, while shares fell by more than 20% following the announcement.
- Novo Nordisk plans litigation and regulatory action to address knockoff drugs, and market experts note the company underestimated the self-pay obesity segment.
Insights by Ground AI
Does this summary seem wrong?
21 Articles
21 Articles
Drugmaker Novo Nordisk slashes Wegovy sales forecasts, blaming compounding
Compounding pharmacies are crimping sales of Novo Nordisk's obesity drug Wegovy by making what are essentially copies of the name-brand medicine. The company says it trying to stop them.
·Washington, United States
Read Full Article
Danish pharmaceutical giant Novo Nordisk is falling headlong after the continued spread of cheap copies of the company's obesity drug forced management to lower its forecasts for the second time this year. The entire Copenhagen Stock Exchange is dragged down by the fall.
·Stockholm, Sweden
Read Full Article
Only eight to 14 percent growth: What would be a success for other companies is a sign of the crisis for the Danish pharmaceutical company. Especially in the US market there are problems – because of a strong competitor.
·Munich, Germany
Read Full Article
Coverage Details
Total News Sources21
Leaning Left6Leaning Right4Center3Last UpdatedBias Distribution46% Left
Bias Distribution
- 46% of the sources lean Left
46% Left
L 46%
C 23%
R 31%
Factuality
To view factuality data please Upgrade to Premium
